Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New evidence eases some concerns about bone fracture risk with breast cancer drug

24.09.2003


New evidence about the breast cancer drug anastrozole (Arimidex) shows that the incidence of a major side-effect – bone fractures – appears to stabilise after reaching a peak at two years of treatment, easing some of the concerns about the drug.



This finding is the latest to come from evidence provided by the world’s largest international study of breast cancer treatment, the ATAC[1] trial, which compared the aromatase inhibitor anastrozole with breast cancer’s current gold standard hormone treatment tamoxifen, and with both treatments combined.

The trial, involving more than 9,000 post menopausal women in 21 countries, last year revealed that over a median follow-up of patients of 33 months, anastrozole enhanced disease-free survival by 19% and cut the incidence of new tumours in the opposite breast by 58% compared to tamoxifen. This represented an absolute difference of 1.8% in favour of anastrozole. An update at 47 months median follow up showed that the gap had widened to an absolute difference of 2.6% in favour of the newer drug. Overall survival comparisons from the trial should be available next year.


Professor Anthony Howell, chairman of the ATAC steering committee, told a news briefing at ECCO 12 – the European Cancer Conference, that while it was clear that further results were adding to the evidence that anastrozole may in the future supplant tamoxifen doctors needed to be cautious. "We should still wait for that overall survival data next year," he said.

A concern about anastrozole has been the risk of bone fractures. Depriving the body of oestrogen reduces the risk of breast cancer recurring because many breast cancers ’feed’ off this hormone. But, one consequence of oestrogen deprivation is that bones become vulnerable. Aromatase inhibitors such as anastrozole produce profound oestrogen deprivation so it would not be unexpected that women on anastrozole might be more at risk of fractures than those on tamoxifen, a drug that is known to have a mildly positive effect on bone density. Therefore, bone fracture was a pre-defined adverse event in ATAC’s main protocol and one of the important questions posed in the trial was – if anastrozole turned out to be better than tamoxifen at preventing recurrence of breast cancer or of primary tumours in the other breast, would this benefit outweigh the downside of any added incidence of fractures?

Patients’ fracture rates were assessed every six months as a proportion of patients with a first fracture, and these analyses were repeated for fractures of the hip, spine and wrist.

Prof. Howell, a medical oncologist at the Christie Hospital, Manchester, UK said: "We found that at the first analysis, after 31 months median duration of treatment, the incidence of fractures was 5.9% in anastrozole patients compared with 3.7% in tamoxifen patients – nearly 60% greater. But, when the data was updated at 37 months the incidence was 7.1% versus 4.4%, so still around a 60% difference. The risk had not worsened. In fact, the six monthly fracture rates for anastrozole reached a plateau after 24 months with the maximum difference between the two treatments being seen at 18 and 24 months. By the last follow up at 48 months the increase in risk was down to about a third higher for anastrozole. There were similar patterns for fractures of the hip, spine and wrist."

Prof. Howell said: "Anastrozole does lead to an increased bone fracture incidence compared to tamoxifen. But, the positive news is that the fracture rate does appear to peak and then stabilise. So, the overall benefit for patients with early breast cancer remains with anastrozole. We have no idea why the fracture rate stabilises but clearly this is important for patients. It is possible that it will climb again but since the curves have been parallel for some time this seems unlikely.

"It is now important to see what happens when patients stop their treatment after five years and we plan to do bone density measurements at the end of the trial."

The trial shows that the combination of tamoxifen and anastrazole is equivalent to tamoxifen (possibly because anastrozole lowered oestrogen dramatically and there was some evidence that tamoxifen acted as an oestrogen agonist in a low oestrogen environment). It was potentially detrimental, Prof. Howell said, for patients to switch from tamoxifen to anastrozole so the advice was that patients should continue with whichever drug they were on.

He concluded: "It is important that tamoxifen does not suffer from the comparison in this trial because it is still a very good treatment. In developing countries with limited resources to pay for more expensive new drugs it is particularly appropriate to continue to use tamoxifen."



Note: ATAC = Arimidex, Tamoxifen Alone or in Combination. Anastrozole (Arimidex) is an aromatase inhibitor, a class of compounds that inhibit the synthesis of oestrogens from androgens in post-menopausal women.

Further information:
ECCO 12 press office: Sunday 21 September – Thursday 25 September
Tel: 45-3252-4163 or 45-3252-4179
Fax: 45-32524171
Margaret Willson: mobile: 44-797-385-3347 Email: m.willson@mwcommunications.org.uk
Mary Rice: mobile: 44-780-304-8897 Email: mary.rice@blueprintpartners.be
Emma Mason: mobile: 44-771-129-6986 Email: wordmason@aol.com

Margaret Willson | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>